Tocilizumab is recommended for the treatment of severe COVID-19
- PMID: 33038768
- PMCID: PMC7540282
- DOI: 10.1016/j.ebiom.2020.103045
Tocilizumab is recommended for the treatment of severe COVID-19
Conflict of interest statement
H.M.W. and Y.G.Z. are inventors on patent application (CN202010103449.6) submitted by the University of Science and Technology of China that covers the new use of anti-IL-6R antibody for COVID-19.
Comment on
-
Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study.EBioMedicine. 2020 Oct;60:102999. doi: 10.1016/j.ebiom.2020.102999. Epub 2020 Sep 16. EBioMedicine. 2020. PMID: 32950003 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
